Dihydropyridine compound and application thereof to drugs

By developing new dihydropyrimidine compounds and their pharmaceutical compositions, we have solved the problems of activity and resistance in existing anti-HBV drugs, achieved effective inhibition and prevention of hepatitis B virus, and provided safer and more efficient treatment. plan.

CN109678859AActive Publication Date: 2019-04-26SUNSHINE LAKE PHARMA CO LTD
6 Cites 28 Cited by

Patent Information

Application Number
CN201811210586.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-09-10
Filing Date
2018-10-17
Publication Date
2019-04-26
Estimated Expiration
2038-10-17

AI Technical Summary

Technical Problem

Existing anti-hepatitis B virus (HBV) drugs such as interferon and lamivudine have problems with moderate activity, toxic side effects and drug resistance, and there is a lack of effective new drugs to replace existing treatment options.

Method used

A new type of dihydropyrimidine compound and its pharmaceutical composition have been developed, which have good pharmacokinetic properties, solubility, stability and low toxicity. They can effectively inhibit HBV infection and change the structure of the nucleocapsid by interacting with the core protein. angle to accelerate its degradation.

Benefits of technology

The novel compounds and compositions show excellent effects in preventing and treating HBV infection, have less toxicity and high antiviral activity, and can effectively replace existing drugs and reduce or prevent the replication of HBV virus.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.
Need to check novelty before this filing date? Find Prior Art